VISN 4 MIRECC Newsflash
Summer 2019
RESEARCH SPOTLIGHT |
Does genetic big data hold answers for safer, more effective opioid prescribing?
More than half of Veterans are living with some form of chronic pain. Meanwhile, PTSD, depression, alcohol use, and suicide attempts—all disorders that affect Veterans—are associated with high-dose opioid use, and Veterans are twice as likely to die from an accidental overdose than non-Veterans. Therefore, finding ways to precisely target opioid treatment for pain or addiction could improve safety and maximize benefits, thereby advancing care.
VA researchers are looking to the Million Veteran Program (MVP)—now the largest health care system-linked genomic database in the world with more than 750,000 participants—for answers. With his project, Pharmacogenetic Study of Opioid Agonist Treatments in MVP, addiction psychiatrist Kyle Kampman, M.D. along with Henry Kranzler, M.D. of the VISN 4 Mental Illness Research, Education, and Clinical Center at the Corporal Michael J. Crescenz VA Medical Center are searching for genetic predictors of opioid sensitivity. Genetic variants can affect the way a person processes medication, so, for a person with a specific variant, one drug (or a particular dosage of the medication) may be more effective while another may carry less risk. Any new genetic discoveries from this study could potentially help predict a patient’s response to the drug buprenorphine for opioid addiction as well as help providers avoid over- or under-prescribing opioids for managing acute or chronic pain.
Dr. Kampman’s study—one of three MVP projects being conducted by VISN 4 MIRECC investigators—supports the Center’s thematic focus on Precision Mental Health Care by making use of big data (merging the power of the MVP database with the electronic health record) to predict treatment outcomes.
Click here for more information about the Million Veteran Program.
CENTER ANNOUNCEMENT |
Following a presentation in late May, the VISN 4 MIRECC was renewed with full support for an additional five-year period. The reviewers recently provided written feedback, awarding the Center a final average rating in the “excellent” range. The report acknowledged the Center’s unique conceptual focus on Precision Mental Health Care, noting its potential impact for VA in ways not addressed by other programs. It also made note of the Center’s research efforts, which have been bolstered by strong faculty, dedication to high-risk and high-impact projects, successful pursuit of peer-reviewed funding, a high rate of scientific publication, and investment in fostering junior investigators.
PROFESSIONAL HONORS |
Gretchen Haas, Ph.D. was recently recognized by the University of Pittsburgh Department of Psychiatry for excellence in teaching medical students.
FUNDING UPDATE |
Judith Callan, Ph.D., R.N. received VA Rehabilitation R&D Merit funding for her study, Does Adding a Tailored Cognitive Behavioral Therapy (CBT) Mobile Skills App Mediate Higher Rates of Depression Recovery, Adjustment, and Quality of Life in OEF/OIF Veterans Compared to Standard CBT?
Henry Kranzler, M.D. received notice of a P30 grant from the National Institute on Drug Abuse (NIDA) to support the Penn PET Addiction Center of Excellence, which is a collaboration between researchers in the Department of Radiology and the Center for Studies of Addiction at Penn and investigators at Yale University. The Penn PACE will support positron emission tomography studies of opioid use disorder (OUD). Its aim is to use this neuroimaging method to understand risk factors for OUD and co-occurring conditions (such as HIV infection) and their treatment. The researchers intend to extend the effort to include Veterans from the CMCVAMC as well as patients and healthy subjects from the Philadelphia community.
PUBLISHING HIGHLIGHTS |
Mavandadi S, Ingram E, Klaus J, Oslin D. Social Ties and Suicidal Ideation Among Veterans Referred to a Primary Care-Mental Health Integration Program. Psychiatric Services. May 2019. PMID: 31138058 [external]
Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. June 2019.PMID: 31166571 [external]
Volk DW, Lewis DA. Insights into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia. JAMA Psychiatry. June 2019. PMID: 31166594 [external]
Boland E, Goldschmied J, Kayser MS, Gehrman PR. Precision Medicine for Insomnia. Sleep Medicine Clinics. June 2019. PMID: 31375199 [external]
Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, Crystal S, Gaither JR, Gordon AJ, Smith RV, Kember RL, Polimanti R, Gelernter J, Fiellin DA, Tate JP, Kranzler HR, Becker WC; VACS Project Team. Patterns and Correlates of Prescription Opioid Receipt Among U.S. Veterans: A National, 18-Year Observational Cohort Study. AIDS and Behavior. July 2019.PMID: 31317364 [external]
Klee A, Chinman M, Kearney L. Peer Specialist Services: New Frontiers and New Roles. Psychological Services. August 2019. PMID: 31393159 [external]
Sign up for updates.
Archive
